Search results for "Vaccination"
Studies find monoclonal antibodies and remdesivir effective, while vaccine-associated myocarditis is rare
A trial of casirivimab plus imdevimab indicated it reduced risk of hospitalization or death, the CDC urged vaccination during pregnancy and updated its v-safe tool, and an analysis showed that postvaccine myocarditis occurred in men and resolved with conservative treatment.
https://immattersacp.org/weekly/archives/2021/10/05/1.htm
5 Oct 2021
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
Answers and even more questions on COVID-19 vaccines
In a fourth forum from ACP and Annals of Internal Medicine, infectious disease experts Carlos del Rio, MD, FACP, Paul Sax, MD, and Deborah Cotton, MD, MPH, FACP, discussed COVID-19 vaccines and their implementation, as well as other aspects of the pandemic response.
https://immattersacp.org/weekly/archives/2021/03/30/2.htm
30 Mar 2021
Distribution plans, data on vaccines; NIH cautious on latest antibody treatment
The Advisory Committee on Immunization Practices chose clinicians and long-term care residents for priority vaccination, while ACP offered additional input on the topic. The NIH said that casirivimab plus imdevimab should not be standard of care, and the CDC offered recommendations on shortening quarantine.
https://immattersacp.org/weekly/archives/2020/12/08/1.htm
8 Dec 2020
Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021
COVID-19 outcomes in health care workers and over the long term, vaccine evidence and uptake among the latest research
A study found that health care workers hospitalized with COVID-19 had shorter stays, while a survey showed high uncertainty about vaccination. Johnson & Johnson released efficacy data on a one-shot vaccine, and a study identified long-term decreases in function among COVID-19 survivors.
https://immattersacp.org/weekly/archives/2021/02/02/1.htm
2 Feb 2021
New data on delta variant of COVID-19 and vaccines
Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
https://immattersacp.org/weekly/archives/2021/08/31/1.htm
31 Aug 2021
Little health benefit, higher costs likely with extended age limit for HPV vaccination
A modeling study examined four scenarios for extended vaccination in women and men up to ages 26, 30, 40, and 45 years.
https://immattersacp.org/weekly/archives/2019/12/10/1.htm
10 Dec 2019
First COVID-19 vaccine receives interim recommendation, hydroxychloroquine ineffective for prophylaxis, and more
The FDA issued an emergency use authorization for the first mRNA vaccine against SARS-CoV-2, and the CDC's Advisory Committee on Immunization Practices made an interim recommendation for its use in those ages 16 years and older. Other research looked at postexposure prophylaxis, household SARS-CoV-2 transmission, and persistent COVID-19 symptoms.
https://immattersacp.org/weekly/archives/2020/12/15/1.htm
15 Dec 2020